Life Spine Announces 1st Surgical Cases of the PROLIFT® Micro Endoscopic Expandable Spacer System

Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today the first surgical cases of ProLift Micro Endoscopic Expandable Spacer System.

PROLIFT® Micro is a uniquely designed Micro Invasive Expandable Spacer that supports a range of procedures including endoscopic TLIF/PLIF, MIS and open. ProLift Micro is offered in an 8mm width and expands in-situ from 8mm to 13mm. ProLift Micro can be deployed through a Micro Invasive cannula utilizing endoscopic visualization, once inserted, ProLift Micro expands in situ to restore disc height and patient alignment.

Utilizing an endoscopic approach allows the physician to work through a small channel which minimizes the required incision and retraction typically associated with transforaminal lumbar interbody fusions. The endoscope protects surrounding vascular structures and provides real time visualization. ProLift Micro is one of the first systems offering a true, full endoscopic fusion from visualization and disc prep to expandable interbody delivery.

“The Endoscopic approach of ProLift Micro allows for direct visualization at the annulus level. Placement of an interbody is facilitated and secured by the ability to look directly at the cage and achieve optimal positioning with minimal entry for the patient,” said Dr. Anthony Hall – Florida.

ProLift Micro Features and Benefits:

  • Post-packable & Repositionable, In Situ
  • Intuitive Instrumentation Helps Protect Neural Anatomy and Surrounding Vascular Structures
  • Coming Next Year – Fully Endoscopic Spine Procedure Utilizing ProLift Micro, In-house Developed Mixed Reality Vision System and Perioperative Biometric Data Analysis Utilizing Artificial Intelligence (AI)

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.